Big comeback? The Q1 report on biotech is in, and there’s been some sputtering

Big comeback. The Q1 report on biotech is in, and there’s been some sputtering

DealForma’s Chris Dokomajilar has been running the numbers again and backs up some of the things we were already pretty sure about — while raising new questions about just how deep and lasting this biotech recovery can be. Checkout the Endpoints News story

All of this by stage, disease indication, modality, target…

+ 0 k
Licensing Deals
+ 0 k
M&A
+ 0 k
Other Deals
+ 0 k
Funding Rounds
+ 0 k
Company Profiles
+ 0 k
Drug Sales Figures